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Case Presentation
A 49-year-old male farmer with previous diagnosis and treatment
of borderline lepromatous leprosy presented with a pruritic
cutaneous eruption, demonstrated in Figure 1. This occurred while
being treated with prednisone 60 mg (.8 mg/kg) and azathioprine
50 mg per day for leprosy reactive ulnar neuritis. He had noted
worsening of the pruritus over the preceding month. He did not
have any symptoms of cough, dyspnea, fever, or diarrhea.
Over the past 6 months he had been prescribed various dosages
of azathioprine 50–100 mg and prednisone 10–60 mg per day to
control relapsing reactive neuritis. His complete blood count
revealed frequent eosinophilia and he had negative tests for HIV,
hepatitis B and C, and syphilis. He did not have diabetes mellitus.
Diagnosis
Disseminated larva currens. Follow-up and treatment: Stool
parasitology examination revealed Strongyloides stercoralis larvae on
all three samples. Due to the clinical diagnosis of disseminated
larva currens, he was prescribed ivermectin 15 mg for 2
consecutive days (200 mg/kg/day). The prednisone dose was
tapered to 20 mg per day. The pruritus resolved and the creeping
eruption disappeared in few days after treatment (Figure 2), with
no clinical or parasitological recurrence at a 12-month follow-up.
Histopathology of a 4-mm punch biopsy from a lesion on the
patient’s left shoulder demonstrated a mild mid-dermal perivas-
cular lymphocytic inflammatory infiltrate with rare eosinophils,
but no larvae were identified in the sections examined.
Discussion
This case illustrates the exuberant cutaneous manifestations of
larva currens and highlights the importance of primary and
Figure 1. Multiple linear urticarial wheals that expanded serpiginously at approximately 1 cm/15 min, resulting in various tracks in
the back and abdomen.
doi:10.1371/journal.pntd.0001357.g001
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areas during immunosuppressive treatment such as that used for
organ transplantation, oncologic chemotherapy, immunologic
diseases, and leprosy reactions. Recently, the initiation of anti-
TNF therapy was associated with the exacerbation of the S.
stercoralis infection in one rheumatologic patient [1]. Although S.
stercoralis generally causes asymptomatic infection, in the immu-
nocompromised host the number of parasites can increase, leading
to autoinfection [2], dissemination, hyperinfection, and death if
unrecognized [3].
These chronic recurrent serpiginous eruptions are manifesta-
tions of autoinfection by filariform larvae, which are capable of
reinfecting the host by penetrating the intestinal wall or by
transcutaneous entry points [2], such as the perianal and gluteal
area. After reinfection, they disseminate to other organs, including
the skin. The autoinfective cycle occurs at a low level throughout
infection [2], making larva currens a common, but occasional,
phenomenon of few or solitary tracks. However, in an immuno-
compromised host an accelerated autoinfective cycle may ensue,
resulting in generalized pruritic eruption (disseminated larva
currens), with multiple and frequent serpiginous tracks [4]. The
distinction between autoinfection and hyperinfection is quantita-
tive (parasitological load) and is not strictly defined [2].
Hyperinfection triggers a severe, life-threatening syndrome known
as hyperinfection syndrome or ‘‘disseminated strongyloidiasis’’,
which usually presents cutaneous manifestations of vascular injury,
such as petechial or purpuric macules [2]. A distinctive sign in
hyperinfection syndrome is a periumbilical purpuric macule,
known as ‘‘the thumbprint sign’’ [5,6]. Initial transcutaneous S.
stercoralis infection may also present acute cutaneous reactions at
the site of larval entry, such as lower and upper extremities.
Physicians should be able to make a presumptive clinical
diagnosis of larva currens based on the observation of rapidly
moving linear or serpiginous tracks. Differential diagnoses include
dermographism and cutaneous larva migrans. The authors use
pen markings on the extremities of these tracks to easily detect
movement, as illustrated in Figure 1. Skin biopsies frequently fail
to reveal the rapidly moving S. stercoralis [7].
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Figure 2. Complete remission after 1 week of treatment. No lesions on the back and abdomen.
doi:10.1371/journal.pntd.0001357.g002
Key Learning Points
N Presentation of disseminated larva currens as multiple
pruriginous erythematous serpiginous wheals
N Therapeutic immunosuppression is the trigger factor for
dissemination in a patient with S. stercoralis infestation
N Hyperinfection syndrome and death are possible com-
plications of untreated cases;
N Effective treatment is possible with ivermectin 200 mg/
kg/day for 2 days
N Differential diagnosis: cutaneous larva migrans and
dermographism—both can be ruled out by detection
of movement within minutes by pen markings on the
extremities of the tracks on physical examination
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